Loxapine: oral and inhaled formulations explained

Loxapine has been on the market for more than 50 years. For most of that time, it has been a workhorse mid-potency first-generation antipsychotic — clinically useful but not headline-grabbing. Then in 2012, the FDA approved an entirely new formulation: Adasuve, an inhaled loxapine powder for the rapid treatment of acute agitation in adults with schizophrenia or bipolar I disorder. The inhaled version represented a meaningful innovation — the first inhaled antipsychotic ever approved — and gave loxapine a new clinical identity alongside its established oral use.

What loxapine is

Loxapine is a dibenzoxazepine, structurally related to clozapine but with a much narrower receptor profile. It blocks dopamine D2 and serotonin 5-HT2A receptors, with some antihistaminic and modest anticholinergic activity. Its main metabolite, amoxapine, is itself an antidepressant — which contributes to loxapine sometimes being described as having modest mood effects in addition to its antipsychotic action.

Oral loxapine: chronic treatment

Oral loxapine (formerly Loxitane, now generic) is FDA-approved for the treatment of schizophrenia. Typical dosing is 60 to 100 mg/day in divided doses, with the usual range being 20 to 250 mg/day depending on response and tolerance. It is started at lower doses (10 mg twice daily) and titrated. Once-daily dosing is sometimes used at maintenance.

Inhaled loxapine (Adasuve): acute agitation

Adasuve is a single-use inhaler delivering 10 mg of loxapine as a thermally generated aerosol. It is FDA-approved for acute treatment of agitation in adults with schizophrenia or bipolar I disorder. Per the FDA Adasuve prescribing information, the maximum is one dose per 24 hours. Onset of effect is rapid — peak plasma levels in about 2 minutes — and clinical response is typically apparent within 10 to 20 minutes.

Why inhaled?

Acute agitation in psychosis is one of the most challenging clinical situations in psychiatry. Standard treatments — oral medications (slow), intramuscular injections (faster but invasive and frightening), or restraints (last resort) — all have downsides. Inhaled loxapine offered a third option: rapid onset comparable to IM injection, but voluntary and less coercive. The patient cooperates with breathing in the medication, which itself has therapeutic value. Studies showed reduction in PEC (Positive and Emergency Clinical) scale agitation scores within 10 minutes.

The bronchospasm warning

Patients with asthma, COPD, or other airway disease should not receive Adasuve. Pre-administration screening for respiratory conditions is required. The REMS requirement has limited Adasuve's adoption — only certain emergency departments and inpatient units use it.

Side effect profile of oral loxapine

Movement effects

Mid-potency profile — more EPS, akathisia, and TD risk than most second-generation drugs but less than haloperidol or fluphenazine. See EPS overview and akathisia management.

Sedation

Moderate, related to its antihistaminic activity.

Weight gain and metabolic effects

Modest. Less than olanzapine or quetiapine, similar to risperidone. Standard metabolic monitoring still recommended.

Anticholinergic effects

Mild to moderate — dry mouth, constipation, blurred vision.

Hyperprolactinemia

Common, with the usual menstrual, breast, and sexual side effects. See hyperprolactinemia article.

Cardiovascular effects

Modest QTc prolongation possible. Orthostatic hypotension uncommon at typical doses.

Seizure threshold

Loxapine modestly lowers seizure threshold; risk increases at high doses or with rapid increases.

Drug interactions

Loxapine is metabolised by multiple CYP enzymes. CNS depressants amplify its sedative effect. Combining with other QT-prolonging drugs requires caution.

Who tends to do well on oral loxapine

• People who responded well to it before
• People who want a mid-potency first-generation option with manageable side effects
• People for whom cost is a major factor — generic loxapine is inexpensive
• People who tolerate the dosing schedule (typically twice daily)

Who might choose differently

• People with prior bad EPS
• People with respiratory conditions (especially relevant for Adasuve)
• People needing once-daily dosing exclusively
• People who responded better to second-generation agents

The bigger picture: rapid-acting options

Adasuve's adoption has been more limited than initially hoped, partly because of the REMS requirements and partly because intramuscular options remain widely familiar to emergency staff. But the concept it introduced — rapid, voluntary, non-injection acute treatment — remains influential. Future agents may build on the same idea.

Practical questions to ask your prescriber

• What dose and schedule are we starting at?
• What baseline labs and monitoring will we do?
• What side effects should I watch for?
• If I have asthma or COPD, what does that mean for any future use of Adasuve?

The big picture

Loxapine has had two distinct lives — as a steady, affordable, mid-potency first-generation antipsychotic for chronic schizophrenia treatment, and as the unusual rapid-onset inhaled treatment for acute agitation. The oral form remains a reasonable option for some patients, particularly those for whom cost matters or who have responded to it before. The inhaled form occupies a specialised role in select emergency settings. Like every antipsychotic, the right fit depends on the full clinical picture, weighed carefully with a prescriber who knows you.

This article is for educational purposes only and is not medical advice. Information is summarised from publicly available FDA labelling and peer-reviewed literature. Always consult your prescribing clinician before starting, stopping, or changing any medication.